Broadening I–O clinical trial participation to improve health equity & diversity: current perspectives & future plans

How can the I–O space ensure cancer immunotherapy trials are accessible to the maximum number of patients who could benefit from them? In this interview, Roisin McGuigan, Editor, Immuno-Oncology Insights, speaks to (pictured left to right) ASCO’s Julie Gralow, Chief Medical Officer and Executive Vice President and Elizabeth Garrett-Mayer, Vice President, Center for Research and Analytics about the current clinical trial landscape for immunotherapy, including current barriers to trial recruitment and strategies to improve the diversity of trial participants.

Please enter your email to access content Read now